000 | 01991 a2200517 4500 | ||
---|---|---|---|
005 | 20250515191018.0 | ||
264 | 0 | _c20091231 | |
008 | 200912s 0 0 eng d | ||
022 | _a1879-114X | ||
024 | 7 |
_a10.1016/j.clinthera.2009.08.012 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPanettieri, Reynold A | |
245 | 0 | 0 |
_aComparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. _h[electronic resource] |
260 |
_bClinical therapeutics _cAug 2009 |
||
300 |
_a1716-23 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdministration, Inhalation |
650 | 0 | 4 |
_aAdrenergic beta-Agonists _xadministration & dosage |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aArea Under Curve |
650 | 0 | 4 |
_aBronchodilator Agents _xadministration & dosage |
650 | 0 | 4 | _aCross-Over Studies |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 |
_aEthanolamines _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aForced Expiratory Volume _xdrug effects |
650 | 0 | 4 | _aFormoterol Fumarate |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aLeast-Squares Analysis |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNebulizers and Vaporizers |
650 | 0 | 4 |
_aPulmonary Disease, Chronic Obstructive _xdrug therapy |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aTime Factors |
700 | 1 | _aMacIntyre, Neil | |
700 | 1 | _aSims, Michael | |
700 | 1 | _aKerwin, Edward | |
700 | 1 | _aFogarty, Charles | |
700 | 1 | _aNoonan, Michael | |
700 | 1 | _aClaus, Raymond | |
700 | 1 | _aAndrews, William T | |
773 | 0 |
_tClinical therapeutics _gvol. 31 _gno. 8 _gp. 1716-23 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clinthera.2009.08.012 _zAvailable from publisher's website |
999 |
_c19203155 _d19203155 |